129 related articles for article (PubMed ID: 8678540)
1. [Relationship of intracellular concentration and duration of contamination of pirarubicin and adriamycin in human bladder cancer cell lines and human bladder normal mucosa cell line].
Saika T; Tsushima T; Nasu Y; Akebi N; Ohmori H
Gan To Kagaku Ryoho; 1996 Jun; 23(7):905-9. PubMed ID: 8678540
[TBL] [Abstract][Full Text] [Related]
2. [A randomized study of pirarubicin (THP) versus adriamycin (ADM) for intravesical instillation therapy against superficial bladder cancer].
Kawamura J; Tochigi H; Obata K; Ueda K; Otaguro K; Kuriyama M; Shinoda M; Naruse K; Murase T; Hasegawa Y
Hinyokika Kiyo; 1992 Mar; 38(3):379-85. PubMed ID: 1523998
[TBL] [Abstract][Full Text] [Related]
3. [Appropriate intravesical retention time of pirarubicin concentration based on its level in tumor tissue, anti-tumor effect and side effect in intravesical instillation therapy for bladder tumor].
Kobayashi M; Sugaya Y; Yuzawa M; Ochi M; Morita T; Kobayashi Y; Tokue A; Hara Y
Gan To Kagaku Ryoho; 1998 Sep; 25(11):1771-4. PubMed ID: 9757205
[TBL] [Abstract][Full Text] [Related]
4. [Fundamental studies on intravesical instillation of 4'-epi-adriamycin for the treatment of bladder cancer].
Tsushima T
Hinyokika Kiyo; 1985 Nov; 31(11):1945-56. PubMed ID: 3867286
[TBL] [Abstract][Full Text] [Related]
5. In vitro antitumor activity of 4'-O-tetrahydropyranyladriamycin on human gastric cancer cells.
Yamaue H; Tanimura H; Noguchi K; Shono Y; Iwahashi M; Hotta T; Tani M; Tsunoda T; Nishimoto N; Terasawa H; Nakamori M
Anticancer Res; 1996; 16(1):243-6. PubMed ID: 8615614
[TBL] [Abstract][Full Text] [Related]
6. [Intravesical chemotherapy of (2''R)-4'-O-tetrahydropyranyladriamycin in bladder tumor].
Masuda H; Hirose J; Suzuki K; Tajima A; Aso Y
Gan To Kagaku Ryoho; 1986 Jul; 13(7):2411-4. PubMed ID: 3729494
[TBL] [Abstract][Full Text] [Related]
7. [The role of protein kinase C alpha in recurrence of superficial bladder carcinoma].
Zhu YY; Wang HM; Kong CZ; Liu DH; Li ZL; Sun ZX; Liu GF
Zhonghua Wai Ke Za Zhi; 2005 May; 43(10):662-6. PubMed ID: 16008942
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of (2''R)-4'-O-tetrahydropyranyl adriamycin on human gastric cancer cell lines in vitro and in vivo.
Saikawa Y; Kubota T; Kuo TH; Furukawa T; Kase S; Tanino H; Ishibiki K; Kitajima M; Hoffman RM
Anticancer Res; 1994; 14(2A):469-73. PubMed ID: 8017850
[TBL] [Abstract][Full Text] [Related]
9. [Investigation of retention time of intravesical instillation therapy with pirarubicin (THP)].
Sugano O; Shoji N; Hatakeyama T; Kato H
Gan To Kagaku Ryoho; 1996 Aug; 23(9):1169-74. PubMed ID: 8751805
[TBL] [Abstract][Full Text] [Related]
10. [Tissue concentration of intravesically instilled (2"R)-4'-o-tetrahydropyranyl-adriamycin or adriamycin in superficial bladder cancer].
Saika T; Tsushima T; Nasu Y; Noda M; Akebi N; Kaku S; Takamatsu M; Ohmori H; Uno S; Johsen T
Nihon Hinyokika Gakkai Zasshi; 1993 Jul; 84(7):1206-10. PubMed ID: 8355436
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of doxorubicin in human bladder tumors.
Gan Y; Wientjes MG; Badalament RA; Au JL
Clin Cancer Res; 1996 Aug; 2(8):1275-83. PubMed ID: 9816297
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic advantages of pirarubicin over adriamycin after intraarterial hepatic administration in the rabbit VX2 tumor model.
Munck JN; Riggi M; Rougier P; Chabot GG; Ramirez LH; Zhao Z; Bognel C; Ardouin P; Herait P; Gouyette A
Cancer Res; 1993 Apr; 53(7):1550-4. PubMed ID: 8453622
[TBL] [Abstract][Full Text] [Related]
13. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
Mizutani Y; Yoshida O; Miki T; Bonavida B
Clin Cancer Res; 1999 Sep; 5(9):2605-12. PubMed ID: 10499639
[TBL] [Abstract][Full Text] [Related]
14. Comparative investigation on use of (2''R)-4'-O-tetrahydropyranyl-adriamycin and adriamycin as intravesical chemotherapy for superficial bladder tumors.
Akaza H; Niijima T; Hisamatsu T; Fujigaki M
Urology; 1988 Aug; 32(2):141-5. PubMed ID: 3400139
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitory and apoptosis regulating effects of adriamycin on different human breast cancer cell lines].
Yu ZY; Zuo WS; Wei L; Shan PY; Song XR; Liu YT; Liu YS; Zhou ZB; Shao ZM
Zhonghua Yi Xue Za Zhi; 2005 Jan; 85(1):19-22. PubMed ID: 15808069
[TBL] [Abstract][Full Text] [Related]
16. [Postoperative prophylactic intravesical instillation of tetrahydropyranyl-adriamycin (THP) for superficial bladder cancer].
Kanayama H; Yokota K; Kurokawa Y; Kagawa S; Yokozeki H; Inai T; Ogawa I; Akazawa S; Hashimoto H; Mizuta K
Gan To Kagaku Ryoho; 1999 Apr; 26(5):651-5. PubMed ID: 10234296
[TBL] [Abstract][Full Text] [Related]
17. [Antitumor effect of pirarubicin (THP) against human colon cancer transplanted into nude mice and the mechanism of cell cycle progression].
Kataoka K; Naomoto Y; Muro M; Kojima K; Horiki S; Hizuta A; Tanaka N; Orita K
Gan To Kagaku Ryoho; 1992 Mar; 19(3):367-71. PubMed ID: 1543363
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin.
Hong WS; Jung HY; Yang SK; Kim HR; Min YI
Anticancer Res; 1997; 17(5A):3613-6. PubMed ID: 9413212
[TBL] [Abstract][Full Text] [Related]
19. [Shock wave therapy of the rabbit VX2 bladder cancer--THP-ADM concentration in the tissue after combination therapy of THP-ADM and shock wave].
Suzuki K; Orikasa S; Hoshi S; Kuwahara M; Yoshikawa K; Ohyama C; Satou M; Kawamura S
Nihon Hinyokika Gakkai Zasshi; 1993 Jun; 84(6):1007-12. PubMed ID: 8345717
[TBL] [Abstract][Full Text] [Related]
20. [A randomized study on intravesical pirarubicin (THP) chemoprophylaxis of recurrence after transurethral resection of superficial bladder cancer].
Miki T; Nonomura N; Kojima Y; Okuyama A; Nakano E; Kiyohara H; Fujioka H; Koide T; Wakatsuki A; Kuroda H; Sugao H; Seguti T; Takeyama M; Yamaguchi S
Hinyokika Kiyo; 1997 Dec; 43(12):907-12. PubMed ID: 9488944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
